STAT3 and neoplasm: Since SHP099, differently from MEK inhibitors, failed to induce STAT3 activation in B16F10 cells (Fig 3A), these results raise the possibility that STAT3 activation may be a critical contributor to growth inhibition in B16F10 tumor cells.